Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
XDSL
Buying ACSEF at 4 would indeed be brilliant, Len. I'm going to get me some MSFT at 10, but in the meantime, I got some ACSEF at 5.20 this am.
PAII Patch Acquires 25% Interest in New Multi-Well Oil and Gas Project in World-Class Region of Alberta Canada
Thursday March 10, 8:00 am ET
CALGARY, March 10 /PRNewswire-FirstCall/ - Patch International (PAII: OTCBB), is pleased to announce that the company has signed a Participation Agreement to participate in a gas project located in Alberta, Canada. Patch has acquired a 25% working interest in this project. Drilling operations on this prospect are expected to commence within three weeks.
This major new prospect is located in the producing Bear Canyon region of Northeast Alberta. The total potential of the project is 12 Bcf (Billion cubic feet of gas). The project consists of one initial well, with the potential to drill multiple wells if the first well is successful. The operator has identified three primary targets. The formation of primary interest on this property is the Bluesky at a depth of approximately 1050 meters with reserve estimates of 4-6 Bcf, 2 to 4 Bcf and 1-3 Bcf respectively. An analogy pool within proximity at Balsom has been mapped that has produced 5Bcf. Additional potential downhole zones exist which could substantially increase reserves.
Alberta accounts for 55% of Canada's production. One half of Alberta's oil and gas is exported to the US, providing 5% of US oil consumption and 12% of natural gas consumption. Canada ranks second largest behind Saudi Arabia for proven crude oil reserves with 15% of world reserves. The majority of these reserves are found in Alberta.
David Stadnyk, President of PAII, stated "We are extremely pleased to be involved in drilling this project in an already successful producing area as it will help PAII move closer to its goal of becoming a mid range oil and gas producer. When you look at oil prices currently over $54 US, this is a great time to be adding new oil and gas assets to our growing company. This project has tremendous upside potential and can be financed without any further near- term financing by the company. PAII is still trading at less than half the current asset value and we feel that our marketing program is helping to get the company's story out. This marketing program has just commenced and the majority of the program will take place over the next few months as the news and results from the company's corporate activities are made public. When you consider that the current market capitalization of PAII is approximately $5 million US and the assets currently in the company are valued at more than $10 million US, we feel that with our targeted marketing campaign and additional new projects coming into the company we should bring PAII's value in line with at least the current underlying asset value. This is an exciting time for PAII shareholders and we are looking forward to a tremendous year of growth."
PAII is a junior oil and gas producer that currently earns oil revenue from 19 oil wells. These wells produce a total of approximately 150-200 barrels of oil per day which provides the company with both short-term and long-term cash flow. It is anticipated that these wells will have a life of over 15 years. PAII has properties in North America and has made significant progress on oil and gas opportunities in Algeria, Libya, and Tunisia. PAII has a significant investment in a pharmaceutical company that is currently worth over $10 million US to PAII. The company plans to use the proceeds from this investment to build its oil and gas assets.
For further information visit our corporate website at www.patchenergy.com.
Contact: Investor Relations
Tel: 888-864-7372
Fax: 604-688-5390
Email: info@patchenergy.com
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made on behalf of the Company. All such forward-looking statements are, by necessity, only estimates of future results and actual results achieved by Patch International Inc. may differ materially from these statements due to a number of factors. Patch International Inc. assumes no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such statements. You should independently investigate and fully understand all risks before you make investment decisions
DYSL
DNDT
DFNS
BSQR, oversold
PHPG, I think it can, I think it can . . .
FEMO already surpassed avg daily vol
PAII
Yes, EZEN. This particular rally will end, alas, but it is a stock that will keep on giving. I'm long.
POCI, it's going up now, Missy.
BIPH tambien
EZEN posts postivie results
http://biz.yahoo.com/prnews/050307/nem039_1.html
WOLV
POCI, the low?
PAII, onward
Thanks, my liver's gonna need it. Morning to you, and all the lurkers out at sea.
DCTH, definite gap
NCI Researchers Report Survival and Tumor Results With Delcath Cancer Therapy
Monday March 7, 8:47 am ET
ATLANTA, March 7 /PRNewswire-FirstCall/ -- National Cancer Institute researchers said cancer treatment technology developed by Delcath Systems, Inc. (Nasdaq: DCTH - News) was associated with positive anti-tumor activity in patients with inoperable cancer in the liver in a Phase I dose finding trial and increased overall median survival to 13 months compared to an average survival of 6-9 months for historical controls.
The findings, which detailed a preliminary look at patients with metastatic melanoma in the liver, the largest subset of patients in the Phase I trial, were reported during the Melanoma Session at the Society of Surgical Oncology's 58th Annual Cancer Symposium, March 3-6 in Atlanta, GA, by NCI investigator Jeffrey Farma, MD, a colleague of the study's principal investigator H. Richard Alexander, MD, head of the NCI's Surgical Metabolism Section.
As a follow-up to a presentation at a cancer symposium in Florida in late January 2005, the NCI reported that five of the 15 evaluable patients in the Delcath study have lived longer than 15 months, and one remained alive past 20 months. The survival data is expected to improve as investigators continue follow-up of living patients.
Patients diagnosed with inoperable cancer in the liver experience an average survival time of six to nine months, based on historical data.
The NCI said two-thirds of the 15 patients exhibited anti-tumor activity ranging from stabilization to a complete response. Of those, 50 percent experienced tumor mass reduction of 50 percent or more. The findings were based on radiographic measurement.
Dr. Alexander's research team at the NCI has since started Phase II clinical studies with the Delcath technology to develop further data on safety and efficacy for eventual applications to the FDA for marketing approval.
"The NCI's findings continue to contribute to a strong foundation of positive clinical outcomes with our technology and to its value in treating patients with terminal tumors," said Delcath chief executive officer M. S. Koly. "In addition to continuing follow-up with Phase I patients, Dr. Alexander has informed Delcath that he intends to perform an analysis on quality of life in the recently launched Phase II trial, contrasting the effects of the Delcath therapy on these patients to those experienced by patients undergoing the only current alternative therapies, which are protracted courses of chemotherapy that are extremely toxic and difficult to get through."
"There was broad interest generated by the meeting, with a lot of questions asked by the oncologists about the therapy and results." Dr. Alexander reported to the company. "Good questions were asked and there was encouragement to continue clinical trials to determine the optimal clinical setting to get the maximum benefit."
The Delcath system delivers chemotherapy directly to the liver via the hepatic artery at much higher doses than is possible with traditional intravenous therapy. As blood exits the liver, special Delcath filters trap the chemotherapy, protecting the rest of the body from excessive toxicity. The procedure is repeatable and less invasive than traditional ways of performing isolated perfusion to effect high-dose therapy of specific body organs or regions.
About Delcath
Delcath is a developer of isolated perfusion technology for organ or region-specific delivery of therapeutic agents. Six US and three foreign issued patents cover its technology. The company is headquartered in Stamford, CT.
This release contains "forward-looking statements" based on current expectations but involving known and unknown risks and uncertainties. Actual results or achievements may be materially different from those expressed or implied. Delcath plans and objectives are based on assumptions involving judgments with respect to future economic, competitive and market conditions, its ability to consummate, and the timing of, acquisitions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond its control. Therefore, there can be no assurance than any forward-looking statement will prove to be accurate.
Contact:
M.S. Koly
Chief Executive Officer
Delcath Systems, Inc.
203 323-8668
http://www.delcath.com
Thomas Redington Redington, Inc. 203 222-7399 212 926-1733 http://www.redingtoninc.com
Source: Delcath Systems, Inc.
AHEM, oops, I mean PAII
PAII
BIPH BIPH woo woo woo
Morning . . .
BIPH closed fantastic. Where for art that Mankey?!?!
Nice. BIPH tambien.
Thx for clearing that up.
BIPH
So is the symbol CGHI or CGHI????
Mornin' Missy . . .
Morning, Candice.
I like what you're doing Missy, and even though I disappear sometimes, I've actually spent a lot of time here since the first of the year, and I know I'm up on the plays I've gotten here though they haven't all worked out. I always try to share with you and Candice things that I get wind of, and I try to keep track of things here, but like you said, you post a lot of stocks, and I am limited in the number of stocks I can play (I'm just a poor boy), especially if they don't move quickly, so I can't just hang here all day watching your every move. But I don't know what you can do about that, other than sending me a check. I don't suppose . . .
Just keep doing what you're doing, Missy, and many of us will just have to content ourselves with catching but a bit of your brilliance.
EZTO was a good one, 2nd; bring us more.
My cat's name is Lucy. No kidding. Furthemore, she's the cutest, smartest and most beautiful cat in the world, everyone here's cats notwithstanding.
Hiya, Missy. Not as quick as you gals, I'm finding the market kind of bo-oring today, not paying very close attention.
Yeah, right, I'm at dodo, whatever the hell that is.
yee haw, doo wop she bop, (yawn), rah rah rah
You shouldn't make so much fun of my sleep habits. I'm dreaming of you -- and Candice -- when asleep.
I'm digging thru my closet for my pom poms now.
SWME, me too
Hi, Gals . . back in a while, I think I have some trading to do.